Diagnologix, LLC

San Diego, CA 92127

SBIR Award Summary

Total Number of Awards 6
Total Value of Awards $2.07MM
First Award Date 09/30/13
Most Recent Award Date 08/21/17

Key Personnel

Last Name Name Awards Contact
Shi Guixin Shi 3
BENCHIMOL MICHAEL BENCHIMOL 1
WANG ZHIYONG WANG 2

6 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-16-302
Budget: 08/21/17 - 06/30/18

Umbilical cord blood (UCB) has been an alternative source for patients with hematologic diseases who may be potentially cured by allogeneic hematopoietic cell transplantation. In addition, UCB is an important stem cell source for other promising technologies, such as large-scale ex vivo productions of hematopoietic stem cell (HSC)-derived red bl...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 05/01/16 - 04/30/17

? DESCRIPTION (provided by applicant): The goal of the proposed work is to develop a simple, robust, and cost-efficient circulating tumor cell (CTC) isolation system based on an innovative BUBLES (BUoyancy enaBLEd Separation) technology for point-of- care applications. The feasibility of this technology has been recently established by using ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 05/01/15 - 04/30/16

DESCRIPTION (provided by applicant): The goal of the proposed work is to develop a simple, robust, and cost-efficient circulating tumor cell (CTC) isolation system based on an innovative BUBLES (BUoyancy enaBLEd Separation) technology for point-of- care applications. The feasibility of this technology has been recently established by using targ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 11/15/14 - 04/30/15

DESCRIPTION (provided by applicant): Substitution of abnormal stem cells with healthy cells has been accomplished clinically through hematopoietic stem cell (HSC) transplantation for more than 50 years. Umbilical cord blood (UCB) is an alternative to bone marrow or peripheral blood HSC source for patients with hematologic diseases who need allog...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PAR-14-261
Budget: 09/01/14 - 12/31/14

Abstract There is an unmet need for cost-efficient technologies for high purity isolation of rare circulating tumor cells (CTCs) from blood. An ideal isolation technique should be able to meet the following criteria: (a) minimal processing time;(b) low final sample volume;(c) isolation from large blood volume;(d) low carryover of leukocytes and ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-13-088
Budget: 09/30/13 - 02/28/14

Abstract There is an unmet need for cost-efficient technologies for high purity isolation of rare circulating tumor cells (CTCs) from blood. An ideal isolation technique should be able to meet the following criteria: (a) minimal processing time;(b) low final sample volume;(c) isolation from large blood volume;(d) low carryover of leukocytes and ...